Home Most Read
Most Read
  • Zhe ZHOU, Chengcheng LI, Wenyu LIANG
    World Clinical Drug. 2026, 47(8): 831-836. doi:10.13683/j.wph.2026.08.001

    Post-stroke limb motor disorders often manifest as spasticity, shoulder-hand syndrome and edema, significantly hindering functional recovery and reducing quality of life. Through the synergistic effect of thermal stimulation promoting local microcirculation and the transdermal absorption of active ingredients, traditional Chinese herbal fumigation and washing therapy can dilate local microvessels, improve blood flow and anti-inflammatory analgesia, and also deliver active ingredients through the skin to regulate neural plasticity and muscle tone, showing definite efficacy in relieving pain, reducing swelling and promoting motor function recovery. However, existing studies often have problems such as single-center, small sample size, variable methodological quality, lack of unified standards for the composition of prescriptions and fumigation and washing parameters, and insufficient depth in exploring the mechanism of action. In the future, it is necessary to deeply explore the mechanism of action of Chinese herbal fumigation and washing components, establish standardized operation procedures, and combine modern technical approaches to optimize treatment plans, so as to promote the standardized application and development of Chinese herbal fumigation and washing in the field of post-stroke rehabilitation.

  • Jiehui ZHAO, Junli ZUO
    World Clinical Drug. 2026, 47(8): 837-840. doi:10.13683/j.wph.2026.08.002

    Hypertension is a major global health concern closely associated with cardiovascular morbidity and mortality. While conventional antihypertensive drugs can effectively lower blood pressure, treatment strategies still require optimization to address challenges such as refractory hypertension and drug side effects. Traditional Chinese medicine(TCM), with its multi-target therapeutic approach, has gained increasing attention as an alternative or adjunctive treatment for hypertension. This article summarized recent advances in TCM for hypertension management, with particular focus on active components, pharmacological mechanisms, and clinical evidence.

  • Xiaolei CAO, Te LI, Zhuoran ZHANG, Hui TIAN
    World Clinical Drug. 2026, 47(8): 864-870. doi:10.13683/j.wph.2026.08.005
    Objective

    To explore the effect of icariin on bleomycin-induced pulmonary fibrosis in mice by regulating PTEN induced putative kinase(PINK)1/E3 ubiquitin ligase(Parkin) mediated mitochondrial autophagy.

    Methods

    Mice were divided into normal group, model group, low- and high-dose icariin groups, and an autophagy inhibitor group, with 10 mice in each group. Lung histopathology, mitochondrial changes, apoptosis, and hydroxyproline(HYP) levels were examined. Serum levels of reactive oxygen species(ROS), superoxide dismutase(SOD), and malondialdehyde(MDA)were measured. Protein expression in lung tissue was detected via Western blotting.

    Results

    The model group exhibited pulmonary edema, significant collagen fiber proliferation, inflammatory cell infiltration, and swollen mitochondria with a small number of mitophagosomes. The apoptosis rate, along with HYP, ROS, and MDA levels, were significantly higher than those in the normal group(P<0.05), whereas SOD, PINK1, and Parkin levels were lower(P<0.05). In the low-and high-dose icariin groups, lung tissue damage progressively improved, the number of mitophagosomes increased sequentially, and the apoptosis rate, HYP, ROS, and MDA levels decreased compared with those in the model group, while SOD, PINK1, and Parkin levels were elevated(P<0.05). The autophagy inhibitor group partially reversed the aforementioned changes observed in the high-dose icariin group.

    Conclusion

    Icariin may activate the mitochondrial autophagy mediated by PINK1/Parkin and inhibit the pulmonary fibrosis induced by bleomycin in mice.

  • Zhengding DENG, Xueqin WANG, Gang XUE
    World Clinical Drug. 2026, 47(8): 886-891. doi:10.13683/j.wph.2026.08.008
    Objective

    To observe the therapeutic effect of Guizhi Sanqi Powder in the treatment of diabetic foot ulcers.

    Methods

    A total of 104 patients with diabetic foot ulcers who were treated in the outpatient and inpatient departments of Rugao Hospital of Traditional Chinese Medicine from June 2024 to July 2025 were selected. Using the variable block randomization method, the patients were randomly divided into the treatment group and the control group at a ratio of 1∶1, with 52 cases in each group. The control group received conventional treatment, while the treatment group was treated with Guizhi Sanqi Powder in addition to the treatment of the control group. The area reduction rates of the wounds in the two groups were compared. The changes in ankle-brachial index(ABI), superoxide dismutase(SOD), malondialdehyde(MDA), interleukin(IL)-1β, tumor necrosis factor(TNF)-α, C-reactive protein(CRP), endostatin(ES), vascular endothelial growth factor(VEGF), fasting plasma glucose(FPG), and 2-hour postprandial blood glucose(2hPG)levels before and after treatment were examined.

    Results

    After treatment, the area reduction rate of the wound in the treatment group was higher than that in the control group(P<0.05). After treatment, the levels of IL-1β, TNF-α, CRP, MDA and ES in both groups decreased compared with those before treatment, and the decrease was more significant in the treatment group(P<0.05). After treatment, the levels of SOD, VEGF, and ABI increased in both groups compared with those before treatment, and the increase was more significant in the treatment group(P<0.05). The levels of FPG and 2hPG in both groups decreased(P<0.05), but there was no statistically significant difference between the groups(P>0.05). No significant adverse reactions occurred in either group during the treatment period.

    Conclusion

    Guizhi Sanqi Powder has a good therapeutic effect on diabetic foot ulcers.

  • Yuxuan SHAN, Zhufeng MA, Yujun GAN, Chunxia HUANG
    World Clinical Drug. 2026, 47(8): 871-878. doi:10.13683/j.wph.2026.08.006
    Objective

    To analyze the effect of folic acid intervention on cardiac remodeling in patients with H-type hypertension based on methylenetetrahydrofolate reductase(MTHFR) C677T gene polymorphism.

    Methods

    A total of 485 patients with hypertension admitted from February 2023 to May 2025 were selected, including 262 patients with H-type hypertension and 223 patients with non-H-type hypertension. The ventricular remodeling indicators and MTHFR gene polymorphism were compared between H-type and non-H-type hypertension patients. Patients with H-type hypertension were divided into the conventional group and the intensive group and received different doses of folic acid intervention.The baseline data, ventricular remodeling indicators and homocysteine(Hcy) levels before and after treatment were compared between the two groups. The correlation between Hcy and ventricular remodeling indicators was analyzed.

    Results

    The left ventricular mass(LVM), left ventricular mass index(LVMI) and interventricular septal thickness(IVST)of patients with H-type hypertension were higher than those with non-H-type hypertension(P<0.05), the MTHFR C677T genotypes of patients with H-type hypertension and non-H-type hypertension were significantly different(P<0.05).After treatment, the LVMI, LVM, IVST, and Hcy levels in the intensive group were lower than those in the conventional group(P<0.05). After treatment, Hcy level was positively correlated with LVMI, LVM, and IVST(P<0.05).

    Conclusion

    MTHFR C677T genotype polymorphism is associated with ventricular remodeling in patients with H-type hypertension.Supplementation of high-dose folic acid can improve cardiac remodeling in patients with H-type hypertension by reducing Hcy level, providing a reference for clinical intervention of cardiac remodeling in patients with H-type hypertension.

  • Jing WANG, Junhong DOU
    World Clinical Drug. 2025, 46(8): 823-829. doi:10.13683/j.wph.2025.08.014
    Objective

    To investigate the effects of ginkgo leaf extract and armillaria mellea powders oral solution in coronary atherosclerotic heart disease(CAHD) with blood stasis syndrome combined with diabetes mellitus after percutaneous coronary intervention(PCI).

    Methods

    A total of 94 patients with CAHD and diabetes mellitus admitted to the Department of Cardiology, Shuangqiao Hospital, Chaoyang District, Beijing from January 2021 to November 2021 were selected. All patients received PCI treatment and were randomly divided into the control group(n=47, receiving conventional treatment) and the experimental group(n=47, receiving conventional treatment plus ginkgo leaf extract and armillaria mellea powders oral solution) through matched randomization. The differences of oxidative stress indexes,immune function indexes and serum cystatin(Cys)C expression levels before and after treatment were compared between the two groups.

    Results

    The expression levels of superoxide dismutase and glutathione peroxidase in experimental group were significantly higher than those in control group after treatment(P<0.05). The expression levels of immunoglobulin(Ig)G, interleukin-6 and IgM in experimental group were significantly higher than those in control group after treatment(P<0.05). The expression level of serum CysC in experimental group after treatment was significantly lower than that in control group(P<0.05). The clinical efficacy of the experimental group was higher than that of control group(91.49% vs. 73.91%, P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).

    Conclusion

    Ginkgo leaf extract and armillaria mellea powders oral solution can significantly improve the oxidative stress response and immune function of patients with CAHD complicated with diabetes after PCI, reduce the level of serum CysC, improve the clinical efficacy, and can be widely applied in clinical practice.

  • Xiaofeng HOU, Donghong LIANG, Xiaobin FAN, Haikun LUO
    World Clinical Drug. 2026, 47(8): 901-906. doi:10.13683/j.wph.2026.08.010
    Objective

    To observe the regulatory effect of ilaprazole combined with compound glutamine enteric capsules on gastric mucosal healing and oxidative stress factors in patients with acute erosive gastritis(AEG).

    Methods

    A total of 96 AEG patients admitted to our hospital from August 2023 to July 2025 were selected as research subjects and randomly divided into the control group and the observation group, with 48 cases in each group. The control group was treated with ilaprazole combined with hydrotalcite, while the observation group was additionally treated with compound glutamine enteric capsules. Both groups received treatment for 14 days. The clinical efficacy, gastric mucosal healing status(erosion healing rate, edema resolution rate), incidence of adverse reactions, and the levels of oxidative stress factors[superoxide dismutase(SOD), malondiadehyde(MDA)], motilin(MTL), gastrin(GAS) and pepsinogen(PG)Ⅰwere compared between the two groups.

    Results

    After treatment, the total effective rate of the observation group was higher than that of the control group(97.92% vs. 87.50%, χ2=2.465, P=0.116). The erosion healing rate and edema resolution rate of the observation group were higher than those of the control group, with statistically significant differences(P<0.05). The levels of SOD, MDA, MTL, GAS and PGⅠ in both groups were improved compared with those before treatment, and the improvements were significantly greater in the observation group than in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).

    Conclusion

    Ilaprazole combined with compound glutamine enteric capsules can accelerate the healing process of gastric mucosal injury in AEG patients, regulate the expression of serum oxidative stress factors, and reduce the continuous stimulation of oxidative damage to the gastric mucosa.

  • Jiaxuan WU, Qiang SUN, Xiaoli WU, Qinyi SHU, Ruiyu YANG, Ruixiang XIE
    World Clinical Drug. 2026, 47(8): 933-940. doi:10.13683/j.wph.2026.08.015
    Objective

    To explore the effects of different doses of dexmedetomidine on postoperative delirium(POD)and inflammatory cytokine levels in elderly patients undergoing elective lumbar spinal stenosis(LSS) surgery.

    Methods

    A total of 90 eligible LSS patients who received surgical intervention in the Department of Spinal Surgery in our hospital from January 2024 and June 2025 were selected and randomly divided into three groups: the low-dose group(intraoperative continuous dexmedetomidine infusion at 0.2 μg·kg-1·h-1), the high-dose group(intraoperative continuous dexmedetomidine infusion at 0.5 μg·kg-1·h-1), and the control group(intraoperative continuous normal saline infusion), with 30 cases in each group. Serial assessments were performed at four predefined time points: pre-operation(T0), 1 hour after anesthesia emergence(T1), postoperative day 1(T2) and postoperative day 3(T3). The Mini-Mental State Examination(MMSE)scores, and the levels of interleukin(IL)-6, IL-10 and tumor necrosis factor(TNF)-α were recorded.

    Results

    At T3, the incidence of POD in the low-dose, high-dose and control groups was 6.67%, 13.33% and 26.67%, respectively. The difference between the low-dose group and the control group was statistically significant(P<0.05). In terms of the POD duration, the duration in the low-dose group, high-dose group and control group was 72.32(64.82, 81.19)h, 93.55(82.98, 108.99)h and 97.57(86.87, 115.23)h, respectively. The POD duration in the low-dose group was significantly shorter than those in the other two groups. In terms of MMSE scores, there were no significant differences among the three groups at T0 and T3(P>0.05). At T1, the MMSE scores of the low-dose group and the control group were both significantly higher than that of the high-dose group(P<0.05). At T2, the MMSE score in the low-dose group was significantly higher than those in the other two groups(P<0.05). From T1 to T3, the levels of IL-6 and TNF-α in the high-dose group were significantly lower than those in the control group(P<0.001), and the level of IL-10 was significantly higher(P<0.001).Correlation analysis revealed that POD was significantly positively correlated with IL-6 and TNF-α levels at T3 point, and significantly negatively correlated with IL-10 level at T3 point.

    Conclusion

    For elderly patients undergoing LSS surgery, perioperative administration of low-dose dexmedetomidine can substantially reduce POD incidence and shorten POD duration without compromising postoperative emergence quality. The underlying mechanism may be closely related to inhibiting the massive release of IL-6 and TNF-α, and upregulating the anti-inflammatory cytokine IL-10.

  • Jie ZHANG, Yudan WANG, Yi WANG, Yilei CONG, Enhong ZHENG, Hua YANG
    World Clinical Drug. 2026, 47(8): 892-900. doi:10.13683/j.wph.2026.08.009

    To evaluate the clinical efficacy of Qidan Tangshen granules in patients with diabetic nephropathy(DN)with Qi deficiency, blood stasis, and kidney deficiency syndrome.

    Methods

    A total of 86 DN patients with Qi deficiency, blood stasis, and kidney deficiency syndrome who visited the department of endocrinology, Longhua hospital affiliated to Shanghai university of traditional Chinese medicine(TCM) from January 2024 to January 2025 were enrolled and randomly assigned to the control group and the treatment group using block randomization, with 43 patients in each group.On the basis of standard treatment, the treatment group additionally received Qidan Tangshen granules, while the control group received a placebo preparation. Both groups received a treatment duration of 12 weeks. After treatment, urinary albumin-creatinine ratio(UACR), glomerular filtration rate(GFR), serum β2-microglobulin(β2-MG), insulin-like growth factor(IGF)-1, superoxide dismutase(SOD), nitric oxide(NO), glutathione reductase(GR), blood glucose, lipid profile, TCM syndrome scores, and safety parameters were observed and compared between the two groups.

    Results

    Finally, 42 patients in the treatment group and 43 in the control group completed the trial. After treatment, the levels of UACR, blood glucose, lipid levels, IGF-1, NO, and SOD in the treatment group were all improved compared with those before treatment(P<0.05). Individual TCM symptom scores for sallow complexion, soreness and weakness of waist and knees, and polyphagia were significantly lower than those in the control group(P<0.05). The overall efficacy rate of Western medicine clinical outcomes was higher in the treatment group than that in the control group(83.3% vs. 60.5%, P<0.05), as was the total effective rate of TCM syndrome improvement(81.0% vs. 55.8%, P<0.05). There were no significant differences in safety indicators or incidence of adverse reactions between the two groups(P>0.05).

    Conclusion

    Qidan Tangshen granules can effectively reduce urinary protein levels in DN patients with Qi deficiency, blood stasis, and kidney deficiency syndrome, improve glucose and lipid metabolism disorders, enhance antioxidant capacity, and significantly alleviate TCM clinical symptoms.

  • Huaiwei WANG, Nanhai LIU, Jingjing HAN, Liping JIA, Yuanyuan ZHAO, Yuhua JIA
    World Clinical Drug. 2026, 47(8): 907-913. doi:10.13683/j.wph.2026.08.011
    Objective

    To compare the thrombolytic efficacy and safety of tenecteplase and alteplase in the treatment of acute posterior circulation infarction(APCI).

    Methods

    A total of 90 patients with APCI admitted to second people's hospital of Mengcheng county from January 2023 to December 2024 were selected as research subjects and randomly divided into the tenecteplase group and the alteplase group, with 45 cases in each group. Both groups received 14 days of treatment. The vascular recanalization rate, levels of neuron-specific enolase(NSE), S100 calcium-binding protein B(S100-β) and 5-hydroxytryptamine(5-HT), National Institutes of Health Stroke Scale(NIHSS) scores, 90-day prognosis and incidence of hemorrhage were compared between the two groups.

    Results

    After treatment, the vascular recanalization rate of the tenecteplase group was higher than that of the alteplase group(60.00% vs. 46.67%), but no significant difference was observed(P>0.05). The levels of NSE and S100-β in the tenecteplase group were lower than those in the alteplase group, while the 5-HT level was higher than that in the alteplase group(P<0.05). The NIHSS scores of the tenecteplase group at 7 days and 14 days after treatment were both lower than those of the alteplase group(P<0.05). The proportion of patients with favorable 90-day prognosis of the tenecteplase group was higher than that of the alteplase group(73.33% vs. 53.33%, P<0.05). There was no statistically significant difference in the total incidence of hemorrhage between the two groups(P>0.05).

    Conclusion

    In intravenous thrombolysis of APCI, there is no significant difference in the incidence of favorable neurological functional outcomes at 90 days after treatment between tenecteplase and alteplase. Tenecteplase has a higher early vascular recanalization rate than alteplase, which can effectively promote the blood flow restoration of ischemic brain tissue and facilitate the repair of neurological function. The overall safety profiles of the two agents are comparable.

News